← ANALYST RATINGS · TIPRANKS
10x Genomics (TXG): analyst forecast and price target
Analyst consensus
Moderate Buy7 Buy9 Hold0 Sell
Ratings of 16 analysts in the last 3 months12-month forecast
Based on 16 price targets given in the last 3 months, the average target is $75.73, the highest $110, the lowest $50.00. The average is +8.4% from the last price of $69.86.
Analyst ratings 23
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $50.00 → $70.00+40.0% | Hold | +0.2% | Reiterated | 16.10.26on TipRanks Oct 17 08:15 | −2.4% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $47.00 → $70.00+48.9% | Hold | +0.2% | Reiterated | 13.10.26on TipRanks 08:41 | −4.5%next day +2.9% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $40.00 → $70.00+75.0% | Hold | +0.2% | Assigned | 12.10.26on TipRanks 09:00 | −6.7%next day −4.5% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $60.00 → $100+66.7% | Buy | +43.1% | Reiterated | 12.10.26on TipRanks 05:10 | −6.7%next day −4.5% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $50.00 → $80.00+60.0% | Hold | +14.5% | Reiterated | 09.10.26on TipRanks 08:10 | +3.8%next day −6.7% · 5 days −11.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $99.00 → $88.00−11.1% | Hold | +26.0% | Downgrade | 07.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $99.00 → $87.00−12.1% | Hold | +24.5% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $97.00 → $87.00−10.3% | Hold | +24.5% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $96.00 → $85.00−11.5% | Hold | +21.7% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $98.00 → $90.00−8.2% | Buy | +28.8% | Upgrade | 07.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $92.00 → $87.00−5.4% | Hold | +24.5% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $52.00 → $110+111.5% | Buy | +57.5% | Reiterated | 07.10.26on TipRanks 03:55 | −5.4%next day +2.0% · 5 days −3.0% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $97.00 → $99.00+2.1% | Buy | +41.7% | Upgrade | 30.09.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $97.00 → $99.00+2.1% | Hold | +41.7% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $96.00 → $97.00+1.0% | Hold | +38.8% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $94.00 → $96.00+2.1% | Hold | +37.4% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $97.00 → $98.00+1.0% | Hold | +40.3% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $94.00 → $92.00−2.1% | Hold | +31.7% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Buy | — | Reiterated | 29.09.26on TipRanks 19:15 | +0.6%next day −1.9% · 5 days −17.7% | ↗ |
| Puneet Souda★★★★★★★★★★#2942 · hits 45% · avg +4.1% | Leerink Partners | $40.00 → $90.00+125.0% | Hold | +28.8% | Reiterated | 29.09.26on TipRanks 08:50 | +1.9%next day +0.6% · 5 days −12.4% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $47.00 → $80.00+70.2% | Hold | +14.5% | Assigned | 28.09.26on TipRanks 06:55 | +4.0%next day +1.9% · 5 days +9.2% | ↗ |
| John Eade★★★★★★★★★★#268 · hits 66% · avg +15.0% | Argus Research | $110 | Buy | +57.5% | Initiated | 25.09.26on TipRanks Sep 28 08:30 | +1.4%next day +4.0% · 5 days +9.3% | ↗ |
| Unknown Analyst | UBS | $20.00 → $68.00+240.0% | Hold | −2.7% | Initiated | 08.09.26on TipRanks Sep 11 05:05 | +5.3%next day +3.0% · 5 days +14.5% | ↗ |
| Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% | RBC Capital | $70.00 | Hold | +0.2% | Initiated | 01.09.26on TipRanks 05:15 | −3.3%next day +2.3% · 5 days +12.1% | ↗ |
| Unknown Analyst | Stephens | $65.00 | Buy | −7.0% | Reiterated | 12.08.26on TipRanks 22:05 | 0.0%next day −3.3% · 5 days +11.8% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $50.00 | Buy | −28.4% | Reiterated | 11.08.26on TipRanks Aug 12 22:05 | +0.2%next day −1.5% · 5 days −4.5% | ↗ |
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $38.00 → $50.00+31.6% | Hold | −28.4% | Reiterated | 10.08.26on TipRanks Aug 11 08:12 | +12.6%next day +0.2% · 5 days −0.9% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $50.00 → $60.00+20.0% | Buy | −14.1% | Reiterated | 10.08.26on TipRanks 07:30 | +12.6%next day +0.2% · 5 days −0.9% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $40.00 | Hold | −42.7% | Assigned | 10.08.26on TipRanks Aug 7 07:50 | +13.5%next day +12.6% · 5 days +7.4% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | — | Hold | — | Reiterated | 07.08.26on TipRanks 15:35 | +13.5%next day +12.6% · 5 days +7.4% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $53.00 | Buy | −24.1% | Reiterated | 07.08.26on TipRanks 08:50 | +13.5%next day +12.6% · 5 days +7.4% | ↗ |
| Name not given | — | $45.00 → $50.00+11.1% | Hold | −28.4% | Reiterated | 07.08.26on TipRanks 07:01 | +13.5%next day +12.6% · 5 days +7.4% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $40.00 → $52.00+30.0% | Buy | −25.6% | Reiterated | 06.08.26on TipRanks Aug 20 04:30 | −3.8%next day +13.5% · 5 days +26.3% | |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $25.00 → $47.00+88.0% | Hold | −32.7% | Reiterated | 15.07.26on TipRanks 08:50 | −0.5%next day −2.2% · 5 days +3.8% | ↗ |
| Justin Bowers★★★★★★★★★★#8679 · hits 47% · avg 0.0% | Deutsche Bank | $17.00 → $23.00+35.3% | Hold | −67.1% | Reiterated | 08.05.26on TipRanks 09:00 | −4.5%next day −5.3% · 5 days −2.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering 10x Genomics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $63.21 at a price of $90.36 (−30.0%); now: $75.73 at $69.86 (+8.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 9 | 10 | 7 | 12 | 11 | 12 |
| Hold | 9 | 9 | 14 | 12 | 16 | 13 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.26 (from $-0.34 to $-0.18). Last quarter: $-0.14.
Sales
Next quarter’s sales estimate — $148M (from $146M to $152M). Last quarter: $151M.
Best top-analyst consensus in the sector · Healthcare
About 10x Genomics
- CEO: Serge Saxonov
- Employees: 1,178
- 6230 Stoneridge Mall Road, Pleasanton, CA, 94588-3260, US
- www.10xgenomics.com
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Data from the stock’s TipRanks forecast page, read 11 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗